Marek Rusin
Overview
Explore the profile of Marek Rusin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
441
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lasut-Szyszka B, Gdowicz-Klosok A, Krzesniak M, Glowala-Kosinska M, Bedzinska A, Rusin M
Apoptosis
. 2024 Jul;
29(9-10):1515-1528.
PMID: 39068622
The FAS ligand (FASLG) is expressed on lymphocytes, which employ it to activate death receptors on target cells. Cancer cells are generally resistant to apoptosis triggered by FASLG. In this...
2.
Krzesniak M, Lasut-Szyszka B, Bedzinska A, Gdowicz-Klosok A, Rusin M
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062022
The p53 tumor suppressor protein activates various sets of genes depending on its covalent modifications, which are controlled by the nature and intensity of cellular stress. We observed that actinomycin...
3.
Rusin M
Postepy Biochem
. 2024 Jul;
70(1):71-87.
PMID: 39016231
The p53 tumor suppressor protein is best known as an activator of cell cycle arrest and apoptosis. Only a fraction of p53-activated genes encode proteins affecting cellular replication and various...
4.
Lasut-Szyszka B, Gdowicz-Klosok A, Malachowska B, Krzesniak M, Bedzinska A, Gawin M, et al.
Chem Biol Interact
. 2024 Mar;
392:110946.
PMID: 38460933
Transcriptomic analyses have revealed hundreds of p53-regulated genes; however, these studies used a limited number of cell lines and p53-activating agents. Therefore, we searched for candidate p53-target genes by employing...
5.
Czapla J, Drzyzga A, Matuszczak S, Cichon T, Rusin M, Jarosz-Biej M, et al.
Front Oncol
. 2023 Sep;
13:1249524.
PMID: 37655095
Introduction: Targeting tumor vasculature is an efficient weapon to fight against cancer; however, activation of alternative pathways to rebuild the disrupted vasculature leads to rapid tumor regrowth. Immunotherapy that exploits...
6.
Lasut-Szyszka B, Rusin M
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108808
The p53 tumor suppressor protein is best known as an inhibitor of the cell cycle and an inducer of apoptosis. Unexpectedly, these functions of p53 are not required for its...
7.
Zajac G, Rusin M, Lasut-Szyszka B, Puszynski K, Widlak P
Acta Biochim Pol
. 2022 Feb;
69(1):205-210.
PMID: 35130377
DNA double-strand breaks induced by ionizing radiation can activate the atypical NF-κB pathway via ATM-mediated phosphorylation of NEMO/IKKγ. We aimed to determine whether the status of p53 influenced the activation...
8.
Lasut-Szyszka B, Malachowska B, Gdowicz-Klosok A, Krzesniak M, Glowala-Kosinska M, Zajkowicz A, et al.
Int J Mol Sci
. 2021 Oct;
22(20).
PMID: 34681730
Co-treatment with actinomycin D and nutlin-3a (A + N) strongly activates p53. Previously we reported that CHIR-98014 (GSK-3 kinase inhibitor), acting in cells exposed to A + N, prevents activation...
9.
Kulach N, Pilny E, Cichon T, Czapla J, Jarosz-Biej M, Rusin M, et al.
Sci Rep
. 2021 Sep;
11(1):18335.
PMID: 34526531
Due to immunosuppressive properties and confirmed tropism towards cancer cells mesenchymal stromal cells (MSC) have been used in many trials. In our study we used these cells as carriers of...
10.
Krzesniak M, Zajkowicz A, Gdowicz-Klosok A, Glowala-Kosinska M, Lasut-Szyszka B, Rusin M
Cell Signal
. 2020 Feb;
69:109552.
PMID: 32032660
Actinomycin D and nutlin-3a (A + N) activate p53, partly through induction of phosphorylation on Ser392. The death of A549 cells induced by A + N morphologically resembles inflammation-inducing pyroptosis...